caa a22 4500 606220895 CHVBK 20210128101126.0 cr unu---uuuuu 210128e20150501xx s 000 0 eng 10.1007/s00380-014-0489-4 doi (NATIONALLICENCE)springer-10.1007/s00380-014-0489-4 Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2 [Elektronische Daten] [Yoshiteru Maeda, Atsushi Suzuki, Junnichi Ishii, Sahoko Sekiguchi-Ueda, Megumi Shibata, Yasumasa Yoshino, Shogo Asano, Nobuki Hayakawa, Kazuhiro Nakamura, Yasukazu Akiyama, Fumihiko Kitagawa, Toshiaki Sakuishi, Takashi Fujita, Shuji Hashimoto, Yukio Ozaki, Mitsuyasu Itoh] Urinary liver-type fatty acid-binding protein (L-FABP) reflects the degree of stress in proximal tubules of the kidney. We examined the level of L-FABP in type-2 diabetes mellitus (T2DM) patients with chronic kidney disease (CKD) stage G1 and G2, and its relationship with cardiac markers and electrocardiographic (ECG) abnormalities. T2DM patients whose estimated glomerular filtration rate (eGFR) was≥60mL/min/1.73m2 were recruited [n=276 (165 males), mean age 64years]. The median level of urinary L-FABP was 6.6μg/gCr. Urinary L-FABP showed significant correlation with urinary albumin-to-creatinine ratio (ACR) (r=0.51, p<0.0001). Median (25th-75th percentile) eGFR was 82 (72-95)mL/min/1.73m2. We divided patients into four subgroups (group 1, L-FABP≤8.4μg/gCr and ACR≤30mg/gCr; group 2, L-FABP≤8.4μg/gCr and ACR>30mg/gCr; group 3, L-FABP>8.4μg/gCr and ACR≤30mg/gCr; group 4, L-FABP>8.4μg/gCr and ACR>30mg/gCr). Compared with group 1, group 4 was significantly higher in systolic blood pressure, and eGFR using standardized serum cystatin C, high-sensitivity troponin T, and N-terminal pro-brain natriuretic peptide (NT-proBNP). Group 4 had significantly higher level of NT-proBNP than group 3. Groups 2, 3 and 4 showed more ECG abnormalities than group 1. These findings suggest that simultaneous measurement of urinary L-FABP and ACR should be useful to assess cardiovascular damage reflecting on the elevation of cardiac markers and ECG abnormalities in T2DM with CKD G1 and G2. Springer Japan, 2014 Urinary liver-type fatty acid-binding protein nationallicence Cardiovascular disease nationallicence Type-2 diabetes nationallicence Chronic kidney disease nationallicence Maeda Yoshiteru Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Suzuki Atsushi Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Ishii Junnichi Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut Sekiguchi-Ueda Sahoko Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Shibata Megumi Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Yoshino Yasumasa Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Asano Shogo Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Hayakawa Nobuki Clinical Pharmacotherapeutics 1, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan aut Nakamura Kazuhiro Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut Akiyama Yasukazu Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut Kitagawa Fumihiko Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut Sakuishi Toshiaki Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut Fujita Takashi Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut Hashimoto Shuji Department of Hygiene, Fujita Health University, Toyoake, Aichi, Japan aut Ozaki Yukio Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan aut Itoh Mitsuyasu Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Heart and Vessels Springer Japan 30/3(2015-05-01), 362-368 0910-8327 30:3<362 2015 30 380 https://doi.org/10.1007/s00380-014-0489-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00380-014-0489-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Maeda Yoshiteru Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Suzuki Atsushi Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Ishii Junnichi Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Sekiguchi-Ueda Sahoko Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Shibata Megumi Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Yoshino Yasumasa Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Asano Shogo Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Hayakawa Nobuki Clinical Pharmacotherapeutics 1, Faculty of Pharmacy, Meijo University, Nagoya, Aichi, Japan aut NATIONALLICENCE 700 1- Nakamura Kazuhiro Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Akiyama Yasukazu Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Kitagawa Fumihiko Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Sakuishi Toshiaki Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Fujita Takashi Joint Research Laboratory of Clinical Medicine, Fujita Health University Hospital, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Hashimoto Shuji Department of Hygiene, Fujita Health University, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Ozaki Yukio Department of Cardiology, Fujita Health University, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Itoh Mitsuyasu Division of Endocrinology, Department of Internal Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 773 0- Heart and Vessels Springer Japan 30/3(2015-05-01), 362-368 0910-8327 30:3<362 2015 30 380